Circulating T cells fuel anti-PD-1 and lenvatinib efficacy

Peter J. Matulich; Megan L. Burger

doi:10.1016/j.ccell.2024.12.003

Circulating T cells fuel anti-PD-1 and lenvatinib efficacy

Peter J. Matulich, Megan L. Burger

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Abstract

The mechanisms underlying synergy between checkpoint blockade and anti-angiogenic therapy remain elusive. In this issue of Cancer Cell, Guo et al. analyze hepatocellular carcinoma patients treated with anti-PD-1 and lenvatinib, identifying a circulating CD8⁺ T cell population critical for treatment efficacy. Engaging these cells could enhance immunotherapy across other settings.

Original language	English (US)
Pages (from-to)	173-175
Number of pages	3
Journal	Cancer Cell
Volume	43
Issue number	2
DOIs	https://doi.org/10.1016/j.ccell.2024.12.003
State	Published - Feb 10 2025

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.ccell.2024.12.003

Cite this

@article{aa080a45cea045f78eaa381bddf1044d,

title = "Circulating T cells fuel anti-PD-1 and lenvatinib efficacy",

abstract = "The mechanisms underlying synergy between checkpoint blockade and anti-angiogenic therapy remain elusive. In this issue of Cancer Cell, Guo et al. analyze hepatocellular carcinoma patients treated with anti-PD-1 and lenvatinib, identifying a circulating CD8+ T cell population critical for treatment efficacy. Engaging these cells could enhance immunotherapy across other settings.",

author = "Matulich, {Peter J.} and Burger, {Megan L.}",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Inc.",

year = "2025",

month = feb,

day = "10",

doi = "10.1016/j.ccell.2024.12.003",

language = "English (US)",

volume = "43",

pages = "173--175",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - Circulating T cells fuel anti-PD-1 and lenvatinib efficacy

AU - Matulich, Peter J.

AU - Burger, Megan L.

PY - 2025/2/10

Y1 - 2025/2/10

N2 - The mechanisms underlying synergy between checkpoint blockade and anti-angiogenic therapy remain elusive. In this issue of Cancer Cell, Guo et al. analyze hepatocellular carcinoma patients treated with anti-PD-1 and lenvatinib, identifying a circulating CD8+ T cell population critical for treatment efficacy. Engaging these cells could enhance immunotherapy across other settings.

AB - The mechanisms underlying synergy between checkpoint blockade and anti-angiogenic therapy remain elusive. In this issue of Cancer Cell, Guo et al. analyze hepatocellular carcinoma patients treated with anti-PD-1 and lenvatinib, identifying a circulating CD8+ T cell population critical for treatment efficacy. Engaging these cells could enhance immunotherapy across other settings.

UR - http://www.scopus.com/inward/record.url?scp=85216884436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85216884436&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2024.12.003

DO - 10.1016/j.ccell.2024.12.003

M3 - Comment/debate

AN - SCOPUS:85216884436

SN - 1535-6108

VL - 43

SP - 173

EP - 175

JO - Cancer Cell

JF - Cancer Cell

IS - 2

ER -

Circulating T cells fuel anti-PD-1 and lenvatinib efficacy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this